Diabetes

Wilmington, NC

107 Diabetes Trials near Wilmington, NC

Power is an online platform that helps thousands of Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

CT-868 for Type 1 Diabetes

Morehead City, North Carolina
This trial is testing a new treatment called CT-868 to see if it helps overweight and obese adults with Type 1 Diabetes control their blood sugar better. Participants will continue their regular insulin therapy and receive either CT-868 or another treatment. The goal is to find out if CT-868 can make blood sugar levels more stable.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

111 Participants Needed

ZT-01 for Type 1 Diabetes

Morehead City, North Carolina
This trial is testing a drug called ZT-01 to help adults with type 1 diabetes who have low blood sugar at night. ZT-01 increases a hormone that raises blood sugar levels. The study will see if ZT-01 reduces nighttime low blood sugar episodes and check its safety.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

186 Participants Needed

Maridebart Cafraglutide for Obesity

Morehead City, North Carolina
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

999 Participants Needed

CagriSema for Type 2 Diabetes

Morehead City, North Carolina
This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1023 Participants Needed

Cadisegliatin for Type 1 Diabetes

Morehead City, North Carolina
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

150 Participants Needed

LY3457263 for Type 2 Diabetes

Morehead City, North Carolina
The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

240 Participants Needed

Cleerly CAD Staging System for Preventing Heart Disease

Morehead City, North Carolina
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:55+

7500 Participants Needed

Tirzepatide for Type 1 Diabetes and Obesity

Morehead City, North Carolina
The main purpose of this study is to find out how well and how safely tirzepatide works in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 49 weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

905 Participants Needed

LY3841136 + Tirzepatide for Obesity with Type 2 Diabetes

New Bern, North Carolina
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

350 Participants Needed

CIN-102 for Gastroparesis

Fayetteville, North Carolina
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo * To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants will go through the following schedule: * Screening period (1-2 visits) * Lead-in period (1 visit) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * Drug- CIN-102 Dose 1 or 2 * Drug- Placebo

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

288 Participants Needed

Orforglipron for Obesity

Fayetteville, North Carolina
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1200 Participants Needed

Orforglipron for Type 2 Diabetes and Obesity

Fayetteville, North Carolina
The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

600 Participants Needed

Eversense CGM for Diabetes

Smithfield, North Carolina
This study is evaluating whether a continuous glucose monitor may help people with diabetes better manage their blood sugar.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

925 Participants Needed

CNP-103 for Type 1 Diabetes

Smithfield, North Carolina
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 208-day study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (90 days).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12 - 35

72 Participants Needed

IcoSema for Type 2 Diabetes

Greenville, North Carolina
This trial will compare IcoSema, a new treatment combining two medicines, to insulin glargine in people with type 2 diabetes. The study targets those whose blood sugar isn't controlled by other oral medicines. IcoSema helps the body use sugar more effectively and reduces appetite to manage blood sugar levels. Insulin glargine is a long-acting insulin commonly used with oral antidiabetic drugs to improve blood sugar control in patients with type 2 diabetes.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

474 Participants Needed

HDV-Insulin Lispro for Type 1 Diabetes

Greenville, North Carolina
The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

230 Participants Needed

MiniMed™ 780G System for Type 2 Diabetes

Greenville, North Carolina
This trial is testing the MiniMed™ 780G system, which includes an insulin pump and sensors, in adults aged 18-80 with type 2 diabetes who need insulin. The device continuously checks blood sugar levels and automatically adjusts insulin delivery to keep blood sugar stable. The study will last several months and involve up to 575 participants across the United States. The MiniMed™ 780G system is an advanced hybrid closed-loop system that has been previously tested in various populations, including adolescents and adults with type 1 diabetes, showing improvements in blood sugar control.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

575 Participants Needed

Very Low Calorie Diet for Obesity and Type 2 Diabetes

Greenville, North Carolina
Roux-en-Y (RYGB) gastric bypass reduces the size and capacity of the stomach and bypasses a portion of the small intestine which leads to decreased food intake and higher levels of a gut hormone called GLP-1 (glucagon-like-peptide-1). These changes lead to weight loss, improved blood sugars and often remission of type 2 diabetes but most patients do not qualify or want surgery. The investigators are searching for ways to make the beneficial effects of RYGB available to most type 2 diabetes patients rather than a select few that undergo RYGB. The investigators believe that parts of RYGB can be medically reproduced through a combination of diet and medicine. Once weekly injectable GLP-1 medicine that leads to weight loss and improved blood sugar control in type 2 diabetes are now FDA approved. Optifast is a medically supervised diet that safely reduces calorie intake to 800 calories per day for three months by replacing normal meals with specially prepared bars and shakes which leads to weight loss and improved blood sugar control in type 2 diabetes. Normal meals are then gradually reintroduced over 6 weeks and the bars/shakes are stopped. The investigators hypothesize that Optifast (diet) + once weekly GLP-1 will lead to weight loss and improvement in blood sugar control in type 2 diabetes similar to what is seen after RYGB.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:25 - 75

50 Participants Needed

CSL300 for Kidney Failure

Greenville, North Carolina
This trial is testing CSL300, a new treatment, to see if it helps people with heart disease or diabetes who are on dialysis. The study aims to find the right dose and check if it improves heart health by reducing inflammation.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

2310 Participants Needed

RYBELSUS® for Type 2 Diabetes

Garner, North Carolina
This trial is testing RYBELSUS®, a tablet that lowers blood sugar, in people with type 2 diabetes who need extra treatment. The study will compare RYBELSUS® to other similar tablets over several months. Participants will have regular doctor visits and complete some questionnaires. Pregnant or breastfeeding women cannot join. RYBELSUS® is an oral form of a medication that has been used in injectable form for managing type 2 diabetes.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

1262 Participants Needed

Why Other Patients Applied

"I have already lost part of a leg to an infection. I want to try to get this horrific condition under control and get back to my life. It's taken enough."

WY
Diabetes PatientAge: 40

"Years ago, Metformin didn't help. I'm currently on Rybelsus & Farxiga. Not doing me much good. My insurance won't cover any of the injectables. Excited to try something new."

QL
Diabetes PatientAge: 71

"I've been in pain for years. It's been crippling and has massively impacted my life. I want to be free. Diabetes changed everything at 15. Diabetic Type 1 for 20 years. SEVERE Peripheral Neuropathy onset 7-8 years in. Have been living with it since. Have tried every drug, everything. Gaba, lyrica, all opioids, electrical current therapy, massages, acupuncture, cupping, everything. Currently taking low dose of duloxetine, have an insulin pump but its not good enough. Want to try a cutting-edge med."

YN
Diabetes PatientAge: 35

"I have struggled with weight management after having bariatric surgery over 5 years ago and have regained what I have lost. I'm looking to participate in a trial that can help me get my life back under control."

IJ
Diabetes PatientAge: 25

"I have had type 2 diabetes for some time now and would love to be part of a study... should the study drug work out as a successful treatment, then I would be glad to be one of the first patients in line!"

MB
Diabetes PatientAge: 67

Ladarixin for Type 1 Diabetes

Raleigh, North Carolina
This trial is testing ladarixin, a medication that may help protect insulin-producing cells in the pancreas. It targets adolescents and adults who have been diagnosed with type 1 diabetes, especially those with severe cases. The goal is to see if ladarixin can slow down the progression of the disease and keep these cells working longer.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:14 - 45

140 Participants Needed

Derm-Maxx for Diabetic Foot

Sanford, North Carolina
This randomized controlled study evaluates the adjuvant use of Derm-Maxx in patients with diabetic foot ulcers
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

150 Participants Needed

Amniotic Tissue Treatments for Diabetic Foot Ulcers

Raleigh, North Carolina
The purpose of this clinical investigation is to evaluate the safety and efficacy of Amnion/Chorion/Amnion allograft , Amnion/Chorion allograft, and/or Amnion/Amnion allograft, plus Standard of Care (SOC) each versus SOC alone in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

240 Participants Needed

Orforglipron for Obesity

Raleigh, North Carolina
This trial will test a daily pill called orforglipron to see if it helps people who are overweight or obese and have type 2 diabetes lose weight. The study will last over a year and involve multiple visits.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1500 Participants Needed

CagriSema for Type 2 Diabetes

Chapel Hill, North Carolina
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participant will get either CagriSema or "dummy" medicine and which treatment they get is decided by chance. Participant will take the study medicine together with their current diabetes medicine (once-daily insulin with or without metformin). For each participant, the study will last for about one year.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

270 Participants Needed

Frexalimab + Insulin for Type 1 Diabetes

Chapel Hill, North Carolina
This trial is testing a new drug called frexalimab in young people with newly diagnosed Type 1 Diabetes. The goal is to see if it can help their bodies keep making insulin. The study will compare different doses of the drug to find the safest and most effective amount.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 35

192 Participants Needed

Behavioral Approaches for Type 1 Diabetes

Chapel Hill, North Carolina
This study is designed to compare two behavioral approaches to reduce diabetes distress ("the expected burdens, concerns, fears, and threats that arise from the challenges of living with diabetes") in adults with type 1 diabetes. At the study baseline, participants will be randomized to take part in one of two virtual, group-based interventions (the "Primary" intervention) utilizing either an emotions-focused or a problem-solving approach to reduce diabetes distress. After the initial intervention, participants will complete surveys to assess their response to the material. Participants who are determined to be "non-responders" (i.e., the Primary intervention was not effective) will be re-randomized to one of two "Supplementary" interventions, which will include individualized sessions to learn and/or practice strategies related to either the psychological or problem-solving approach.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:30+

200 Participants Needed

Metformin vs Insulin for Gestational Diabetes

Chapel Hill, North Carolina
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Sex:Female

1572 Participants Needed

Optimal Timing of Childbirth for Gestational Diabetes

Chapel Hill, North Carolina
This study will conduct a randomized trial among women with gestational diabetes (GDM). Study of Pregnancy And Neonatal health (SPAN), TIMing of dElivery (TIME) is a randomized trial that will recruit up to 3,450 pregnant women with uncontrolled GDM and randomize the timing of their delivery. Women with GDM who are approached for the trial and are found eligible but do not consent to participating in randomization for delivery will be asked to consent for chart review only (estimated additional n=3,000). The primary objective is to determine the best time to initiate delivery for GDM-complicated deliveries (defined as the time when risk of illness and death for the newborn is the lowest) between 37-39 weeks.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Sex:Female

6450 Participants Needed

GNTI-122 for Type 1 Diabetes

Durham, North Carolina
This is a 78-week single arm, multi-center, Phase 1 study to evaluate the safety, tolerability, cellular kinetics, and biomarker changes in C-peptide over time of GNTI-122, an investigational cell therapy manufactured from a participant's own blood cells in adult participants with recently diagnosed T1D. After assessment of eligibility, participants who qualify for the study will be enrolled sequentially in 1 of 3 cohorts. Cohort 1 participants (n=3) receive a low dose of GNTI-122 . Cohort 2 participants (n=3) receive a high dose of GNTI-122. Cohort 3 participants (n=10) receive a high dose of GNTI-122 in combination with rapamycin. Participants are followed for 78 weeks after the administration of GNTI-122 during which safety and efficacy assessments are made, including vital signs, ECG, physical exam, clinical labs, and monitoring of adverse events and concomitant medications. Disease markers (e.g., MMTT-stimulated C-peptide, HbA1c) and pharmacodynamic activity (e.g., lymphocyte subsets and phenotypes, effector T cell responses to islet antigens ex vivo, T1D autoantibodies) will be monitored serially throughout the study. The study will include sentinel dosing and a Safety Review Committee to ensure participant safety.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 45

16 Participants Needed

1234

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Diabetes clinical trials in Wilmington, NC pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Diabetes clinical trials in Wilmington, NC work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Diabetes trials in Wilmington, NC 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Wilmington, NC for Diabetes is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Wilmington, NC several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Diabetes medical study in Wilmington, NC?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Diabetes clinical trials in Wilmington, NC?

Most recently, we added GNTI-122 for Type 1 Diabetes, Management Program for Chronic Kidney Disease in Type 2 Diabetes and Screening Program for Chronic Kidney Disease in Type 2 Diabetes to the Power online platform.

What is the best treatment for diabetes?

There isn’t one “best” therapy—think of diabetes care as two layers. First, everyone benefits from diabetes education, a balanced diet, regular activity, and routine monitoring. Second, medicines are chosen by diabetes type and other health issues: type 1 always needs insulin (preferably with a continuous glucose monitor or hybrid pump), while type 2 usually starts with metformin plus lifestyle changes and, if more help is needed, adds a GLP-1 or SGLT2 drug (especially when heart, kidney, or weight problems exist) before considering insulin. Work with your healthcare team to revisit these steps every few months so treatment keeps pace with your goals and any new health changes.

How much weight do you need to lose to reverse type 2 diabetes?

Most studies find that you need to shed about 10–15 % of your starting weight—roughly 15 kg (33 lb) for an average-sized adult—to give yourself the best shot at putting type-2 diabetes into remission (normal sugars without diabetes pills). The closer you are to diagnosis and the more weight you keep off—especially if you can pass the 15 kg mark—the higher the odds (up to 80 % in some trials), while smaller losses still improve blood sugar but rarely achieve full remission. Work with your healthcare team to choose a safe approach (intensive diet program, GLP-1 medications, or bariatric surgery) and to monitor that blood-sugar targets stay on track once the weight comes off.

Can diabetics still get Ozempic?

Yes—if you have type-2 diabetes and meet NICE criteria (poor glucose control despite other drugs, or need for weight loss/heart-protection), your GP or diabetes nurse can still prescribe Ozempic; it is not used for type-1 diabetes, pregnancy, or in children. The practical hurdle is the current UK supply shortage, so existing users should order repeats early and stay in touch with their pharmacist, while new patients may need to start a similar medicine (e.g., dulaglutide) until stock returns.

When will oral insulin be available?

No insulin pill has been approved yet. The most advanced candidates (such as insulin tregopil and ORMD-0801) are still redesigning or preparing large Phase 3 studies, and newer “chocolate-capsule” nano-formulations have not even begun human trials until at least 2025. If upcoming studies succeed, regulatory review and manufacturing mean that everyday prescription use is unlikely before the late-2020s at the earliest.

Why is type 2 diabetes not curable?

Type 2 diabetes isn’t considered curable because its root problems—body-wide insulin resistance and gradual loss of insulin-producing β-cells—can return whenever weight or lifestyle slips, and adult β-cells don’t fully regrow once lost. Big, sustained weight loss (through diet, bariatric surgery, or powerful medications) can put the disease into remission for years, but the underlying susceptibility remains, which is why regular follow-up and healthy habits must continue even when blood sugar is normal.

Can I stop taking metformin when my sugar is back to normal?

Normal readings don’t necessarily mean diabetes is cured; for many people the numbers stay normal only because metformin is on board, and stopping it without a plan can let sugars creep back up. Talk with your clinician about whether you truly meet “remission” criteria (HbA1c < 6.5 % for at least 6 months, stable weight, good kidney function); if so, you can try a monitored dose-reduction, check home glucose and repeat labs in 3 months, and restart the drug promptly if levels rise. In short, never quit metformin on your own—make it a shared, step-by-step decision that includes a taper and clear follow-up.

Can a person fully recover from diabetes?

Type 1 diabetes cannot presently be cured; people need lifelong insulin. In type 2 diabetes, some individuals—especially soon after diagnosis—can achieve remission (normal blood-sugar readings without diabetes medicines) through substantial, sustained weight loss or bariatric surgery, but the underlying tendency can return, so regular check-ups remain essential. So while you may control or even “switch off” type 2 diabetes for a time, no form of diabetes is considered permanently gone.

Which country has the cure for diabetes?

No country has an approved, take-home “cure” for diabetes; the Chinese cell-therapy result you may have seen was a one-patient, early-stage experiment that still needs larger trials and regulatory review. Worldwide teams—from China to the United States, Canada, Europe and beyond—are testing stem-cell implants, gene editing and immune therapies, but for now the proven way to stay healthy is tight glucose monitoring, modern medications (e.g., metformin, GLP-1 or insulin) and lifestyle changes, with bariatric surgery offering remission for some people with type 2 diabetes. Stay alert for peer-reviewed trial results and discuss any experimental option with your diabetes specialist before pursuing treatment abroad.

What is the record trial for diabetes?

RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) was a 5-year study of 4,458 adults with type 2 diabetes that compared adding rosiglitazone to metformin or a sulfonylurea versus the standard metformin-plus-sulfonylurea combination. It showed no overall difference in cardiovascular deaths or hospitalisations (hazard ratio 0.99), but rosiglitazone roughly doubled the risk of heart-failure events and increased bone fractures; these safety concerns, rather than glucose control, ultimately led regulators and doctors to curb use of the drug.

What is the A1C goal for a 70 year old?

For a 70-year-old who already has diabetes, guidelines use a sliding scale: aim below about 7–7.5 % if the person is otherwise healthy and independent, below 8 % if they have multiple illnesses or mild functional decline, and up to 8.5 % if they are frail or in long-term care—these higher limits reduce the risk of dangerous low-blood-sugar episodes. If the 70-year-old is only being screened, the usual cut-offs still apply (normal < 5.7 %, pre-diabetes 5.7-6.4 %, diabetes ≥ 6.5 % confirmed). Work with the healthcare team to choose the target that balances day-to-day safety with long-term benefit.

Popular Searches

By Condition

Depression Clinical Trials in North Carolina

Anxiety Clinical Trials in North Carolina

Schizophrenia Clinical Trials in North Carolina

ADHD Clinical Trials in North Carolina

Bipolar Disorder Clinical Trials in North Carolina

Multiple Sclerosis Clinical Trials in North Carolina

Autism Clinical Trials in North Carolina

Treatment Resistant Depression Clinical Trials in North Carolina

Borderline Personality Disorder Clinical Trials in North Carolina

Social Anxiety Disorder Clinical Trials in North Carolina

Parkinson's Disease Clinical Trials in North Carolina

Alzheimer's Disease Clinical Trials in North Carolina

By Location

Clinical Trials near Durham, NC

Clinical Trials near Charlotte, NC

Clinical Trials near Winston-Salem, NC

Clinical Trials near Chapel Hill, NC

Clinical Trials near Raleigh, NC

Clinical Trials near Asheville, NC

Clinical Trials near Greensboro, NC

Clinical Trials near Greenville, NC

Clinical Trials near Wilmington, NC

Clinical Trials near High Point, NC

Clinical Trials near Goldsboro, NC

Clinical Trials near Hickory, NC

Other People Viewed

By Subject

25 Weight Loss Trials near Raleigh, NC

220 Clinical Trials near Henderson, NC

14 Glaucoma Trials near Raleigh, NC

166 Clinical Trials near Concord, NC

155 Clinical Trials near Flat Rock, NC

Top Clinical Trials near Garner, NC

Top Clinical Trials near Fayetteville, NC

Top Clinical Trials near Denver, NC

Top Clinical Trials near Carrboro, NC

Top Clinical Trials near Calabash, NC

Top Clinical Trials near Belmont, NC

Top Clinical Trials near Asheboro, NC

By Trial

Phosphatidylserine for Type 2 Diabetes

Insulin Management Strategies for Diabetes during Pregnancy

Oral Semaglutide for Type 2 Diabetes in Youth

Artificial Pancreas for Type 1 Diabetes

Continuous Glucose Monitoring for Diabetes

Family Matters Intervention for Childhood Obesity

LY3841136 + Tirzepatide for Obesity with Type 2 Diabetes

Exercise for Type 2 Diabetes

Audio Recordings for Diabetes Management

Sleep Optimization for Type 1 Diabetes

Intensive Glycemic Control for Gestational Diabetes in Overweight/Obese Women

HD-tDCS for Hand Function Improvement

Related Searches

Focused Ultrasound for Tremors in Parkinson's Disease

Mobile App for Arthritis

Pre-Treatment Physical Therapy for Acoustic Neuroma

Genetic Screening and MRI for Prostate Cancer

Isatuximab + Lenalidomide for Multiple Myeloma

Top Clinical Trials near Burien, WA

Zanubrutinib + Obinutuzumab + Sonrotoclax for CLL or SLL

VIP943 for Blood Cancers

Vagus Nerve Stimulation for Anxiety in Autism

Online Parenting Program for Families of Middle School Students

HMPL-689 for Lymphoma

Online Peri-operative Education for Head and Neck Cancer Surgery

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial